A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections - Full Text View

Sponsor:	Memorial University of Newfoundland
Collaborator:	Eastern Health
Information provided by:	Memorial University of Newfoundland
ClinicalTrials.gov Identifier:	NCT00528008

Purpose

The purpose of this study is to find out if chlorhexidine gluconate solution is better at reducing the rate of wound infection after cesarean section compared to povidone-iodine.

Condition	Intervention	Phase
Wound Infection	Other: povidone-iodine solution Other: chlorhexidine gluconate	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Povidone-Iodine vs. Chlorhexidine Gluconate - A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections

Resource links provided by NLM:

MedlinePlus related topics: Cesarean Section Surgery

Drug Information available for: Chlorhexidine Chlorhexidine digluconate Povidone-iodine Hibiclens Cadexomer iodine Gluconic acid D-Gluconic acid, monosodium salt Manganese gluconate Iodine Povidone

U.S. FDA Resources

Further study details as provided by Memorial University of Newfoundland:

Primary Outcome Measures:

to determine the rate of wound infection using two standard wound preparations: povidone-iodine and chlorhexidine gluconate [ Time Frame: within 6 weeks following surgery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

readmission to hospital [ Time Frame: within 6 weeks following surgery ] [ Designated as safety issue: No ]
extended length of admission [ Time Frame: within 6 weeks following surgery ] [ Designated as safety issue: No ]
need for intravenous antibiotics [ Time Frame: within 6 weeks following surgery ] [ Designated as safety issue: No ]
need for repeat procedure such as drainage [ Time Frame: within 6 weeks following surgery ] [ Designated as safety issue: No ]
increased outpatient surveillance [ Time Frame: within 6 weeks following surgery ] [ Designated as safety issue: No ]

Estimated Enrollment:	494
Study Start Date:	December 2007
Estimated Study Completion Date:	November 2009
Estimated Primary Completion Date:	November 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Active Comparator povidone-iodine	Other: povidone-iodine solution Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
B: Active Comparator chlorhexidine gluconate	Other: chlorhexidine gluconate Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.

Detailed Description:

Wound infection is a universal potential morbidity to any type of surgery. Over the years many studies have been completed to evaluate ways to decrease this morbidity. Recent literature has looked at different types of surgical solutions used in pre-operative cleansing. Chlorhexidine and povidone-iodine are two standard surgical prep solutions used on a global scale. The most recent literature has shown that chlorhexidine has a decreased wound infection rate for longer surgeries. Cesarean section, as a surgical time, varies from 20 - 60 minutes. There has been no known literature regarding wound infection rates using these two solutions in elective cesarean sections. This trial will review the rates of wound infection using chlorhexidine and povidone-iodine during elective cesarean section and determine if there is any statistically significant difference between the two solutions. The results could potentially decrease wound infection rates, decrease morbidity, decrease hospital length of stay, and help to guide further surgical management.

Eligibility

Ages Eligible for Study:	19 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Age >19 years
Gestational age > 37 weeks
Booked elective cesarean section

Exclusion Criteria:

Gestational age < 37 weeks
Premature rupture of membranes
Onset of labor prior to procedure
Evidence of maternal sepsis; maternal fever > 38.5C
LSCS for emergency issues: non-reassuring fetal status, placental abruption, failed induction

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00528008

Contacts

Contact: Donna R Hutchens, BN, RN

709-777-7471

donna.hutchens@easternhealth.ca

Locations

Canada, Newfoundland and Labrador
Women' s Health Centre, Eastern Health	Recruiting
St. John's, Newfoundland and Labrador, Canada, A1E 5K9
Contact: Donna R Hutchens, BN, RN 709-777-7471 donna.hutchens@easternhealth.ca
Principal Investigator: Jillian Carpenter, MD
Sub-Investigator: Atam Gill, MD, FRCSC
Sub-Investigator: Joan Crane, MD, FRCSC
Sub-Investigator: Donna Hutchens, BN, RN
Sub-Investigator: Merlee Steele-Rodway, RN

Sponsors and Collaborators

Memorial University of Newfoundland

Eastern Health

Investigators

Principal Investigator:

Jillian Carpenter, MD

Resident, Obstetrics and Gynecology, Memorial University of Newfoundland

More Information

No publications provided

Responsible Party:	Memorial University of Newfoundland, Obstectrics/Gynecology Resident ( Dr. Jillian Carpenter )
Study ID Numbers:	HIC07.33
Study First Received:	September 10, 2007
Last Updated:	August 26, 2008
ClinicalTrials.gov Identifier:	NCT00528008 History of Changes
Health Authority:	Canada: Ethics Review Committee

Keywords provided by Memorial University of Newfoundland:

infection
sepsis
povidone-iodine
chlorhexidine gluconate
fever

erythema
leukocytosis
drainage
vaginal discharge
elective cesarean section

Additional relevant MeSH terms:

Anti-Infective Agents
Communicable Diseases
Chlorhexidine
Growth Substances
Physiological Effects of Drugs
Hematologic Agents
Wounds and Injuries
Disorders of Environmental Origin
Trace Elements
Povidone-Iodine
Infection
Pharmacologic Actions

Anti-Infective Agents, Local
Disinfectants
Chlorhexidine gluconate
Therapeutic Uses
Blood Substitutes
Povidone
Iodine
Micronutrients
Plasma Substitutes
Dermatologic Agents
Wound Infection

ClinicalTrials.gov processed this record on November 27, 2009